MetaCap

Indaptus Therapeutics Inc. (INDP)

NASDAQ: INDPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.82-0.31 (-9.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INDP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$433.16M
EPS (TTM)
-$3.16
52-week range
0.92 – 5.96
Day range
2.78 – 3.16
Volume / Avg
239.36K / 712.87K
Beta
—

52-week range

$0.92$5.96

INDP stock today

Indaptus Therapeutics (INDP) closed at $2.82 on Nov 20, down 9.90% (-$0.31), versus the S&P 500's 3.70% decline. Trading was light, with 239.36K shares changing hands, about 34% of the average daily volume. Shares are 52.7% below their 52-week high of $5.96, set on Jun 4, 2026 and 206.5% above the 52-week low of $0.92, in the middle of the past year's range.

INDP is down 3.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.4%. Indaptus Therapeutics has posted a net loss over the last twelve months (EPS of -$3.16), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Indaptus Therapeutics

Company profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Junyi Dai
Headquarters
New York, NY
Employees
5

Financial highlights

Full financials

Indaptus Therapeutics reported a net loss of $20.8 million, compared with a loss of $15.0 million a year earlier. Diluted earnings per share came in at -$21.58.

Indaptus Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-20.85M$-15.02M$-15.42M$-14.32M$-7.71M
EPS (diluted)$-21.58$-44.96$-1.83$-1.73$-1.89

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.01 vs —

INDP news

All INDP news

Indaptus Therapeutics peers

Health Care sector
INDP peer companies
CompanyPrice% ChgMarket capCompare
EOLSEvolus Inc.6.52-6.86%$431.55Mvs INDP
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs INDP
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs INDP
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs INDP
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs INDP
ARVNArvinas Inc.6.46-4.15%$423.03Mvs INDP
PRTAProthena Corporation plc8.22-2.14%$422.10Mvs INDP
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs INDP

Indexes, lists and sector

Indaptus Therapeutics stock FAQ

What is Indaptus Therapeutics's stock price today?

INDP last traded at $2.82 as of Nov 20, 4:00 PM EST, down 9.90% on the day. Prices are delayed at least 15 minutes.

Does Indaptus Therapeutics pay a dividend?

No. Indaptus Therapeutics does not currently pay a regular cash dividend.

Who is Indaptus Therapeutics's CEO?

Mr. Junyi Dai is the chief executive officer of Indaptus Therapeutics Inc., which has about 5 employees.

Has INDP ever split its stock?

Yes. The most recent INDP stock split was a 1-for-28 split on Jun 27, 2025, one of 3 splits on record.

What is the INDP 52-week high?

The 52-week high for INDP is $5.96 and the 52-week low is $0.92. The stock is currently 52.7% below its high.

Compare INDP